Skip to main content
. 2016 Jun 3;9:3381–3386. doi: 10.2147/OTT.S105672

Table 2.

Levels of tumor markers in patients with oral/oropharyngeal squamous cell carcinoma, benign tumor, and healthy control group (M)

Groups Cyfra21-1
(ng/mL)		 SCCAg
(ng/mL)		 Ferritin
(ng/mL)		 CEA
(ng/mL)		 CA19-9
(µ/mL)		 AFP
(ng/mL)
Oral/oropharyngeal squamous cell carcinoma 2.39 0.90 200.80 6.79 10.36 3.01
Stage I + II 2.14 0.73 150.10 2.10 9.74 2.89
Stage III + IV 2.54 1.06 234.85 2.94 10.52 3.03
Benign tumor 1.61** 0.61* 154.65* 1.87* 8.72 2.79
Healthy persons 1.39** 0.60* 113.49* 1.48* 10.33 2.73
P1 <0.001 <0.001 <0.001 <0.001 0.082 0.585
P2 <0.001 <0.001 <0.001 <0.001 0.149 0.632
P3 0.043 <0.001 0.002 <0.001 – –
P4 <0.001 0.981 0.964 0.430 – –
P5 <0.001 0.953 0.059 0.054 – –
P6 <0.001 <0.001 <0.001 <0.001 – –
P7 <0.001 <0.001 <0.001 <0.001 – –
P8 0.170 0.934 0.050 0.155 – –

Notes: The data were analyzed using Kruskal–Wallis nonparametric rank sum test, the comparison among groups was performed using Mann–Whitney U test. The measurement data were analyzed using M. P1 was the comparison result between patients with OSCC/OPSCC, benign tumor group, and healthy group. P2 was the comparison result between early oral/oropharyngeal squamous cell carcinoma (stage I + II) group, patients with middle-late OSCC/OPSCC (stage III + IV), benign tumor group, and healthy people. P3 was the comparison result between early and patients with middle-late OSCC/OPSCC. P4 was the comparison result between the early group and benign tumor group. P5 was the comparison result between the early stage group and health control group. P6 was the comparison result between the middle-late group and benign tumor group. P7 was the comparison result between the middle-late group and healthy control group. P8 was the comparison result between the benign tumor group and healthy group.

**

showed comparison with the early group, P-value <0.05;

*

showed comparison with the middle-advanced stage, P-value <0.05.

Abbreviations: AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; Cyfra21-1, cytokeratin 19 fragment; M, median; P, patients; OSCC/OPSCC, oral/oropharyngeal squamous carcinoma; SCCAg, squamous cell carcinoma antigen.